(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
ISS astronauts spy airglow and dwarf galaxy | Space photo of the day for Jan. 13, 2026 - 2Instructions to Pick the Right Tires for Your Slam 1500.
- 3Computerized Domains d: A Survey of \Vivid Undertakings\ Computer generated Reality Game
- 4The race is on to turn your body into a GLP-1 factory
- 5The cheap health insurance promoted by Trump officials has this catch
- NASA is shooting for the moon. A guide to the Artemis II mission
- White House responds to Sabrina Carpenter after pop star slams 'evil' ICE video using her song
- At least 171 measles cases confirmed in 9 states, CDC data shows
- Instructions to Pick the Right Dental Expert for Teeth Substitution
- 5 Chiefs That Changed Our Opinion on Film
- Find the Captivating Professional flowerbeds of the US
- Massive supernova explosion may have created a binary black hole
- Shrapnel hits across central Israel, injuring several, causing property damage
- Top notch Feasting: A Manual for Worldwide Acclaimed Eateries
